Overview

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of triacetyluridine, fluorouracil, and leucovorin in treating patients who have unresectable, locally advanced, or metastatic cancer of the esophagus or stomach.

Phase:

Phase 2

Details

Lead Sponsor:

Southwest Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Calcium
Fluorouracil
Leucovorin
Levoleucovorin